Drug
Cabozantinib S Malate
Cabozantinib S Malate: highest development phase Phase 2, developed by Exelixis, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Exelixis, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cabozantinib S-malate NCT01811212 | Phase 2 | Poorly Differentiated Thyroid Gland Carcinoma |
| Cabozantinib S-malate NCT04878029 | Phase 1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation |
Latest
No recent events.
Follow Cabozantinib S Malate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.